A comparison of amount and speed of deposition between the pari lc star® jet nebulizer and an investigational eflow® nebulizer

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 24, Issue 3, 2011, Pages 157-163

  Coates, Allan L ^a,b   Green, Maria ^a   Leung, Kitty ^a   Chan, Jeffrey ^a   Ribeiro, Nancy ^a   Ratjen, Felix ^a   Charron, Martin ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

deposition; efficient; lung delivery; nebulizers

Indexed keywords

PENTETATE TECHNETIUM TC 99M; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; LUNG CLEARANCE; LUNG EXAMINATION; MALE; NEBULIZATION; NEBULIZER; OSMOLARITY; PARI EFLOW; PARI LC STAR; RADIATION EXPOSURE; RESIDUAL VOLUME;

ADULT; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 79958238207     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2010.0861     Document Type: Article

References (34)

1. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, and Wohl, MEB: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331:637-642. (Pubitemid 24276863)
2. Ramsey BW, Burns J, and Smith AL: Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis: the results of two Phase III placebo controlled clinical trials. Pediatr Pulmonol. 1997;14:S137-S138.
3. Nikolaizik WH, Vietzke D, and Ratjen F: A pilot study to compare tobramycin 80mg injectable preparation with 300mg solution for inhalation in cystic fibrosis. Can Respir J. 2008;15:259-262.
4. Weers J, Metzheiser B, Taylor G, Warren S, Meers P, and Perkins WR: A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv. 2009;22:131-138.
5. McKoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch- Bogart GZ, and Montgomery AB: Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:921-928.
6. Ratjen F: New pulmonary therapies in cystic fibrosis. Curr Opin Pulm Med. 2007;13:541-546. (Pubitemid 47494205)
7. Katz SL, Adatia I, Louca E, Leung K, Humpl T, Reyes JT, and Coates AL: Nebulized therapy for childhood pulmonary hypertension: an In vitro model. Pediatr Pulmonol. 2006;41: 666-673.
8. Coates AL, Denk O, Leung K, Ribeiro N, Chan J, Green M, Martin S, Charron M, Edwardes M, and Keller M: Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatr Pulmonol. 2010 (in press).
9. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Rys Davies E, and Carswell F: The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med. 1994;88:203-211. (Pubitemid 24130571)
10. Coates AL, Green M, Leung K, Louca E, Tservistas M, Chan J, Ribeiro N, and Charron M: The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times. J Aerosol Med. 2007;20:320-330. (Pubitemid 47463185)
11. Coates G, and O'Brodovich HM; Measurement of pulmonary epithelial permeability with 99mTc-DTPA aerosol. Semin Nucl Med. 1986;16:275-284.
12. O'Brodovich HM, Coates G, Kay J, and Muysson D: Simultaneous measurement of lung clearance rates for Tc- and In-DTPA in normal and damaged lungs. J Appl Physiol. 1989;66:2293-2297. (Pubitemid 19142383)
13. Regnis JA, Robinson M, Bailey DL, Cook P, Hooper P, Chan HK, Gonda I, and Bye PTP: Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med. 1994;150:66-71. (Pubitemid 24209938)
14. Robinson M, Eberl S, Tomlinson C, Daviskas E, Regnis JA, Bailey DL, Torzillo PJ, Menache M, and Bye PTP: Regional mucociliary clearance in patients with cystic fibrosis. J Aerosol Med. 2000;13:73-86. (Pubitemid 30421866)
15. Coates AL, Green M, Leung K, Chan J, Ribeiro N, Louca E, Ratjen F, Charron M, Tservistas M, and Keller M: Rapid pulmonary delivery of inhaled tobramycin for pseudomonas infection in cystic fibrosis: a pilot project. Pediatr Pulmonol. 2008;43:753-759.
16. Leung K, Louca E, Grey M, Tipples GA, and Coates AL: Use of the new generation pharmaceutical impactor for particle size distribution measurements of live biological aerosols. J Aerosol Med. 2005;18:414-426. (Pubitemid 43038407)
17. Leung K, Louca E, and Coates AL: Comparison of breath enhanced to breath actuated nebulizers for rate, consistency and efficiency. Chest. 2004;126:1619-1627.
18. Newman SP, Pitcairn GR, Hirst PH, and Rankin L: Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev. 2003;55:851-867. (Pubitemid 36776797)
19. Zhu X: Dosage of radiopharmaceuticals and internal dosimetry. In: M Charron (ed). Practical Pediatric PET Imaging. Springer, New York; pp. 37-46, 2006.
20. Everard ML: Ethical aspects of using radiolabelling in aerosol research. Arch Dis Child. 2003;88:659-661. (Pubitemid 36930297)
21. Macey DJ, and Marshall R: Absolute quantitation of radiotracer uptake in the lungs using a gamma camera. J Nucl Med. 1982;23:731-735.
22. Pitcairn GR, and Newman SP: Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med. 1997;10:187-198. (Pubitemid 27415413)
23. Coates AL, MacNeish CF, Dinh L, Rollin T, Gagnon S, Ho SL, and Lands LC: accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med. 2000;13: 169-178.
24. O'Callaghan C, Clarke AR, and Milner AD: Inaccurate calculation of drug output from nebulisers. Eur J Pediatr. 1989;148:473-474. (Pubitemid 19049335)
25. Coates AL, MacNeish CF, Lands LC, Smountas A, Meisner D, Kelemen S, and Vadas EB: Factors influencing the rate of drug output during the course of wet nebulization. J Aerosol Med. 1998;11:101-111. (Pubitemid 28259490)
26. Kwong E, MacNeish CF, Meisner D, Kelemen S, Vadas EB, Coates AL: The use of osmometry as a means of determining changes in drug concentration during jet nebulization. J Aerosol Med. 1998;11:89-100. (Pubitemid 28259489)
27. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310. (Pubitemid 16134762)
28. Laube BL, Jashnani R, Dalby RN, Zeitlin PL: Targeting aerosol deposition in patients with cystic fibrosis: Effects of alteration in particle size and inspiratory flows. Chest. 2000;118:1069-1076.
29. Ilowite JS, Gorvoy JD, Smaldone GC: Quantitative deposition of aerosolized gentamycin in cystic fibrosis. Am Rev Respir Dis. 1987;136:1445-1449. (Pubitemid 18030280)
30. Smaldone GC, Fuhrer J, Steigbigel R T, McPeck M: Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1991;143:727-737.
31. Sorenson JA, Phelps DL: Problems in radioactive detection and measurement. In: Physics in Nuclear Medicine. Grune and Gratton Inc., Orlando, FL; pp.208-228,1980.
32. Modi AC, Quittner AL: Barriers to treatment adherence for children with cystic fibrosis: what gets in the way. J Pediatr Psychol. 2006;31:846-858. (Pubitemid 44310212)
33. Ho SL, Kwong WTJ, Coates AL: Evaluation of four breathenhanced nebulizers for home use. J Aerosol Med. 2001;14: 467-475. (Pubitemid 34008103)
34. Mitchell JP, Nagel MW, Nichols S, Nerbrink O: Laser diffractometry as a technique for rapid assessment of aerosol particle size from inhalers. J Aerosol Med. 2006;19:409-433. (Pubitemid 46067762)